Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Entegris heads into its October 29 earnings report with fresh analyst firepower on the bull side and short sellers still adding to positions, a divergence that makes the next two weeks genuinely interesting.
The analyst picture has moved again since the note published six days ago. Barclays initiated with an Overweight rating and a $212 target on October 13. Truist Securities followed a day later with a Buy and a $190 target. These join Stifel's Buy at $200 from October 8, giving the stock three new initiations in one week, all pointing higher. The consensus mean target has moved up to $178.38, around 11% above the current price of $161.16. The 12-month forward EPS estimate trajectory remains the single strongest factor reading on the stock, ranking in the 98th percentile of the universe on year-on-year increase. The analyst recommendation differential also scores in the 91st percentile, meaning the gap between current ratings and the historical norm for this stock is unusually bullish. No downgrades appear in the recent data.
Short sellers are not reading the same memo. Short interest has climbed to 5.7% of the free float, up 4.5% on the week and up 17% over the past month. That monthly build is notable: it began from a base that was already moving higher when the previous note was published, and it has continued through the August earnings rally and the subsequent wave of analyst upgrades. The borrow market remains loose, however. Availability is running at roughly 810%, meaning there are about eight shares available to lend for every one currently borrowed. Cost to borrow is a modest 0.53%, barely changed from prior weeks. There is no squeeze pressure here. Shorts can add or cover freely, and the incremental building looks like a deliberate bet against a richly-priced stock rather than a forced or crowded position.
Options positioning offers little additional drama. The put/call ratio is 0.64, sitting essentially at its 20-day average of 0.63 and within a fraction of a standard deviation of that mean. The 52-week range runs from 0.14 to 1.19, so the current reading is comfortably mid-range. Options traders are neither hedging aggressively nor loading up on calls. The market is, unusually for a stock two weeks from earnings, priced for ambiguity rather than a directional view.
The most relevant recent history sits in the earnings reaction data. The August 4 Q2 print produced a one-day move of 16.3% and a five-day move of nearly 20%. The prior quarter also delivered a double-digit positive move on the day. Both instances produced sharp short covering and analyst upgrades, a pattern that has repeated. The PE multiple is now at 33.5x, with the 30-day change up over 6 points, while EV/EBITDA has drifted slightly lower over the same period to 23.8x. The stock has pulled back 3.4% on the week even as peers have sold off harder: ONTO is down 16% and COHU is down 14% over the same period, making ENTG's relative performance look resilient rather than weak.
Institutional ownership confirms the structural bull case is well-held. BlackRock added over one million shares in the quarter to September 30 to reach 13.4% of shares outstanding. T. Rowe Price added 835,000 shares to reach 8.4%. JP Morgan Asset Management's most recent filing showed an addition of over 2.3 million shares, the largest single quarterly change among the top holders. The activist register shows no 13D filings; all major holders are passive.
What to watch over the next two weeks is whether the short build continues into the print, and whether any of the newly-initiated analysts revise their targets once earnings are digested, given that three of them have set price objectives well above where their peers landed.
See the live data behind this article on ORTEX.
Open ENTG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
